Schonfeld Strategic Advisors LLC Biocryst Pharmaceuticals Inc Transaction History

Schonfeld Strategic Advisors LLC

$15.4 Billion
Q4 2024

A detailed history of Schonfeld Strategic Advisors LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 217,740 shares of BCRX stock, worth $1.87 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

217,740

Previous 171,090 27.27%

Holding current value

$1.87 Million

Previous $1.3 Million 25.92%

% of portfolio

0.01%

Previous 0.01%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$7.03 - $8.43 $327,949 - $393,259	46,650 Added 27.27%	217,740 $1.64 Million
Q3 2024 Nov 14, 2024	SELL	$6.41 - $8.69 $1.8 Million - $2.45 Million	-281,513 Reduced 62.2%	171,090 $1.3 Million
Q2 2024 Aug 14, 2024	BUY	$4.13 - $6.79 $1.87 Million - $3.07 Million	452,603 New	452,603 $2.8 Million
Q2 2023 Aug 14, 2023	BUY	$6.96 - $8.81 $843,113 - $1.07 Million	121,137 New	121,137 $852,000
Q4 2022 Feb 14, 2023	SELL	$10.5 - $14.2 $1.96 Million - $2.65 Million	-186,872 Reduced 89.85%	21,100 $242,000
Q3 2022 Nov 14, 2022	BUY	$10.79 - $14.81 $395,734 - $543,171	36,676 Added 21.41%	207,972 $2.62 Million
Q2 2022 Aug 15, 2022	SELL	$7.89 - $17.88 $918,427 - $2.08 Million	-116,404 Reduced 40.46%	171,296 $1.81 Million
Q1 2022 May 16, 2022	BUY	$11.56 - $19.76 $2.71 Million - $4.63 Million	234,500 Added 440.79%	287,700 $4.68 Million
Q4 2021 Feb 14, 2022	BUY	$11.18 - $15.46 $265,424 - $367,035	23,741 Added 80.59%	53,200 $737,000
Q3 2021 Nov 16, 2021	SELL	$14.21 - $17.65 $1.07 Million - $1.33 Million	-75,628 Reduced 71.97%	29,459 $423,000
Q2 2021 Aug 16, 2021	BUY	$9.5 - $17.24 $811,138 - $1.47 Million	85,383 Added 433.33%	105,087 $1.66 Million
Q1 2021 May 17, 2021	SELL	$7.37 - $13.61 $498,853 - $921,220	-67,687 Reduced 77.45%	19,704 $201,000
Q4 2020 Feb 16, 2021	SELL	$3.37 - $8.61 $519,047 - $1.33 Million	-154,020 Reduced 63.8%	87,391 $650,000
Q3 2020 Nov 16, 2020	BUY	$3.43 - $5.53 $254,447 - $410,231	74,183 Added 44.36%	241,411 $1,000
Q2 2020 Aug 14, 2020	BUY	$1.9 - $5.61 $317,733 - $938,149	167,228 New	167,228 $797,000
Q1 2020 May 15, 2020	SELL	$1.6 - $4.11 $635,625 - $1.63 Million	-397,266 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$1.59 - $3.45 $817,314 - $1.77 Million	-514,034 Reduced 56.41%	397,266 $1.37 Million
Q3 2019 Nov 14, 2019	SELL	$2.5 - $3.73 $3.31 Million - $4.93 Million	-1,322,400 Reduced 59.2%	911,300 $2.61 Million
Q2 2019 Aug 14, 2019	BUY	$2.91 - $9.15 $6.5 Million - $20.4 Million	2,233,700 New	2,233,700 $8.47 Million
Q1 2019 May 15, 2019	SELL	$7.38 - $9.72 $81,180 - $106,920	-11,000 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$6.51 - $9.6 $285,138 - $420,480	-43,800 Reduced 79.93%	11,000 $89,000
Q3 2018 Nov 14, 2018	BUY	$5.52 - $7.99 $302,496 - $437,852	54,800 New	54,800 $418,000

Others Institutions Holding BCRX

# of Institutions

278

Shares Held

167M

Call Options Held

728K

Put Options Held

989K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.6B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.

Account

Schonfeld Strategic Advisors LLC Biocryst Pharmaceuticals Inc Transaction History